Fexagratinib targets FGF, CSF, and VEGF pathways, showing potential in MS treatment by reducing inflammation and promoting ...

The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...

The Quadruple Aim—a framework originally rooted in improving patient experience, enhancing population health, and achieving ...

Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care ...

Amit Saxena, MD, discusses how personalized treatment decisions for lupus nephritis require careful consideration of patient characteristics, multidisciplinary coordination, and emerging guidelines, ...

The complex relationship between possibly impaired cognitive function in patients with multiple sclerosis (MS) and fasting ...

Inteleclinic AI tool automates neuromuscular exam scoring, reducing time and ensuring consistent assessments across settings.

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...

A total of 7 states passed ballot measures during the 2024 presidential election to enshrine abortion access into their state ...

The study evaluated a reduced-intensity conditioning regimen without total body irradiation for alloHCT in DC/TBD patients.

Objectives: We assessed whether proactive care management for artificial intelligence (AI)–identified at-risk patients reduced preventable emergency department (ED) visits and hospital ...